1. India R&D 2007: December 5-6, 2007 at FICCI, Auditorium, New Delhi.
See here for more details of this FICCI conference.
After the success of the last two global conferences organized in Delhi on India R&D 2005 and India R&D 2006.FICCI in partnership with the Department of Science and Technology (DST) and Council of Scientific and Industrial Research (CSIR) is organizing the Third Global Conference on “India R&D 2007- Innovation, Advantage India” on
The objective of the conference is to espouse the diverse Indian approach to innovation, invention and creativity, as they tend to opt for cost effective innovation and also to convince the world on the benefits that would be generated by collaborating and investing in R&D. India in the last few decades has added a number of ‘most preferred’ tags to itself- from being a favored IT hub, to becoming the back office of the world and now, the knowledge center of the world. India is quickly moving up the value chain by becoming a global R&D hub providing cutting-edge research and development. India is also moving ahead in the R&D value chain, with the country increasingly attracting investments in high-end R&D.
2. Challenges to IPR Awareness and Enforcement’: 4th December 2007, FICCI Federation House, New Delhi, India
Another FICCI conference. See FICCI website for more details.
3. “Pharmaceutical and Biotech Patent Law: Recent Developments” : December 13, 2007 from 1:00-2:00 PM (EST).
More details on Donald Zuhn’s excellent blog. Extract below:
“Practising Law Institute (PLI) will be offering a audio-only webcast entitled: The presentation is part of PLI’s One-Hour Patent Hot Topic Briefing series. Speakers David K. Barr and Daniel L. Reisner of Kaye Scholer LLP, co-editors of the PLI treatise “Pharmaceutical and Biotech Patent Law,” will provide an overview of the patent law issues that arise in the drug approval process, from research and development through FDA approval, and will then discuss recent case law decisions that particularly affect the pharmaceutical and biotech industries.
In addition, the speakers will cover the following topics and issues: The drug development process and the types of patents that result from that process. The patent issues that arise during the various phases of the development of a drug product, including early-stage research in drug discovery, preclinical development, clinical trials, and the FDA approval process.
Recent case law developments, including: KSR v. Teleflex — the Supreme Court’s reevaluation of the law of obviousness, Takeda v. Alapharm — the Federal Circuits first pharmaceutical case following KSR, Significant decisions governing the patentability of active pharmaceutical ingredients, including: Sanofi-aventis v. Apotex, Pfizer v. Apotex, and Aventis v. Lupin, In re Seagate Technology — which redefined the standard for establishing willful infringement in patent infringement cases The registration fee for this webcast is $299, and registrants will be entitled to a 40% discount off the price of the PLI treatise “Pharmaceutical and Biotech Patent Law.”
4. IP and Gender: Mapping the Connections: April 4, 2008 | 09:30AM – 04:00PM
For details, see here. Here is the extract from the website:
“In the Spring of 2004, the WCL Program on Information Justice and Intellectual Property, Women and the Law Program, and Journal of Gender, Social Policy, and the Law, sponsored an initial effort to bring scholars together to focus interdisciplinary attention on the interplay between intellectual property and gender.
The following year, we built on the discussions from that first workshop by holding a second program highlighting the work of two scholars writing in this emerging area, Ann Bartow and Sonia Katyal. Following the symposium, these two scholars published their work in the Journal of Gender, Social Policy, and the Law.
In 2006, we held a full day Symposium on intellectual property and gender, leading to a number of works published in the Journal of Gender, Social Policy, and the Law and other publications. Topics we have discussed in our past meetings have ranged from: the impact on intellectual property law and policy on gender-related imbalances in wealth, cultural access, political power, and social control; creative production and gender; the effects of stereotyping and of actual and rhetorical feminization and masculinization of participant roles upon intellectual property stakeholders; the gendered development of IP doctrines and doctrinal categories; related issues in the teaching and practicing of intellectual property; and feminist jurisprudential insights about intellectual property law.”
5. International Generic Pharmaceutical Alliance
For more details, see here: . Abstract below:
“Attendees include the industry’s top executives, many of whom participate in panel discussions, answer questions from conference participants and hear vital information from such organizations as the World Bank, IMS Health, World Trade Organization, World Health Organization, and regulatory agencies, along with Wall Street analysts and legal experts involved in international patent and regulatory litigation.
The annual International Generic Pharmaceutical Alliance conference is the most important gathering of generic industry leaders and policy makers worldwide. This four-day event, organized by the world’s leading generic industry associations, conveys the latest market and regulatory intelligence regarding opportunities emerging in the generic medicines sector. Each year, international experts address the most pressing and relevant business and regulatory issues impacting the international manufacturing, distribution and sale of generic medicines, drawing more than 400 CEOs, senior executives and industry stakeholders in 2006.”